Bristol Myers Squibb (BMS) unveils plans to invest in its first cell therapy factory in Europe.
The company has chosen Leiden in the Netherlands for the new manufacturing site, in order to leverage the growing life sciences region near Amsterdam and for easy access to transportation for cell shipping, according to a statement from BMS. The facility will be equipped with capabilities for multi-product cell therapy manufacturing, and the ability to scale up capacity. The site will leverage innovative technologies and the latest manufacturing equipment, along with advanced digital systems.
“A key element of BMS’ commitment to cell therapy is our continuous investment in advanced manufacturing capabilities, from the expansion of our global network and capacity to treat patients to reduced turn around time and optimized costs,” said Ann Lee, Senior Vice President, Cell Therapy Development & Operations at BMS, in a statement. “We continue to grow our presence in Europe and the Netherlands, which offers an innovative life sciences hub and world class industry talent, and we look forward to hiring several hundred talented people over the coming years to join our global team and participate in our cell therapy journey.”
Planning for site design and development is now underway, with construction anticipated to begin later in the year.